Bellicum was testing the efficacy of BPX-501, an experimental T-cell therapy, to treat blood cancers and inherited blood disorders.
The FDA paused the trial after three patients experienced encephalopathy, a broad term for brain disease, damage or malfunction.
Bellicum acknowledged the encephalopathy cases may be related to the experimental treatment, but noted the three patients who developed the complications had particularly complex medical cases.
“Bellicum is awaiting formal communications from the FDA to determine the requirements for resuming studies, and will be working closely with the FDA to address their questions,” the company said Tuesday.
More articles on supply chain:
3 reasons why drug ads are on the sidelines for Super Bowl LII
Drug prices will be top priority for Azar, says Trump
Drug spend to jump 7.3% for health systems in 2018: 4 report findings
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.